Natera
NTRA
$328.93
+0.86%
Natera, Inc. is a diagnostic and research company that leverages proprietary molecular and bioinformatics technology to develop and commercialize advanced genetic testing products, primarily in the areas of prenatal screening, carrier screening, oncology (molecular residual disease), and organ transplant rejection monitoring. As a leader in the non-invasive prenatal testing (NIPT) market with its Panorama test and a pioneer in the emerging molecular residual disease (MRD) space with Signatera, Natera is recognized for its innovative approach to liquid biopsy and precision medicine. The current investor narrative centers on the company's robust revenue growth, driven by the rapid adoption of Signatera in oncology and expansion into new indications, while the stock has surged over 97% in the past year, reflecting strong market confidence in its long-term growth potential despite ongoing profitability challenges.…
NTRA
Natera
$328.93
Related headlines
Investment Opinion: Should I buy NTRA Today?
Based on the analysis, NTRA is rated a Buy. The company's revenue growth of 38.8% YoY, strong analyst consensus (Strong Buy, average target $336.74), and improving gross margins (64.8%) support this rating. The forward P/S of 5.29x (based on estimated revenue of $5.92B) is more reasonable than the trailing 13.58x, suggesting that if growth continues, the valuation is justified. However, the stock is not cheap, and investors should be prepared for volatility.
Sign up to view all
NTRA 12-Month Price Forecast
The AI model assesses NTRA as bullish over the next 12 months, driven by robust revenue growth and improving margins. However, the high valuation and inconsistent profitability warrant a medium confidence level. The stance would be upgraded if the company demonstrates sustained profitability and revenue growth above 40%, while a downgrade would occur if growth decelerates below 30% or if margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $344.33 and implied upside of +4.7% versus the current price.
Average Target
$344.33
0 analysts
Implied Upside
+4.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $435
Analyst target range
The target price range spans from a low of $280.00 to a high of $375.00, with the average at $336.74. The low target implies a downside of 14.7% from the current price, suggesting that even the most bearish analyst sees limited downside, likely pricing in potential competitive pressures or slower-than-expected adoption of Signatera. The high target implies an upside of 14.3%, reflecting optimism about continued growth and margin expansion as the company scales. The spread between the low and high targets is 34%, indicating moderate uncertainty about the company's future performance. The presence of a strong buy consensus and recent upgrades from multiple firms suggests that analysts are confident in Natera's growth story, but the relatively small upside to the average target indicates that much of the good news is already priced in.
Drowning in data?
Find the real signal!
Bulls vs Bears: NTRA Investment Factors
Natera presents a compelling growth story with accelerating revenue, strong analyst support, and improving margins, but it is offset by a high valuation and ongoing profitability challenges. The bull case is currently stronger, driven by the company's dominant position in high-growth markets and its ability to scale. The most critical tension is whether Natera can achieve sustained profitability while maintaining its rapid growth; if it does, the stock has further upside, but any stumble could trigger a sharp de-rating given the premium valuation.
Bullish
- Accelerating Revenue Growth: Natera's revenue grew 38.8% YoY in Q1 2026 to $696.6M, up from $501.8M in Q1 2025. Sequential acceleration from $476.1M in Q4 2024 to $696.6M in Q1 2026 demonstrates strong and sustained demand for its tests, particularly Signatera.
- Strong Analyst Consensus: With a 'Strong Buy' rating and an average price target of $336.74, analysts see further upside. The high target of $375 implies a 14.3% gain from the current price of $328.18, reflecting confidence in the company's growth trajectory.
- Improving Profitability Trend: Despite a net loss in Q1 2026, the company achieved positive net income of $47.3M in Q4 2025, a significant turnaround from losses in prior quarters. This suggests that scaling operations is driving operating leverage and moving toward sustained profitability.
- High Gross Margin: Gross margin stands at 64.8% (Q1 2026), up from 62.9% in Q4 2024. This high and improving margin indicates strong pricing power and cost efficiency, providing a solid foundation for future profitability as revenue scales.
Bearish
- High Valuation with Negative Earnings: The trailing P/S ratio is 13.58x, and the P/E is negative due to net losses. Even with strong growth, the valuation implies high expectations; any slowdown could lead to significant multiple compression.
- Persistent Net Losses: Natera reported a net loss of $85.1M in Q1 2026, with a net margin of -12.2%. While Q4 2025 was profitable, the overall trend shows inconsistent profitability, raising concerns about the path to sustainable earnings.
- High Beta and Volatility: With a beta of 1.534, the stock is highly sensitive to market movements. The 52-week range of $157.43 to $343.18 shows significant volatility, which may deter risk-averse investors.
- Limited Upside to Average Target: The average analyst target of $336.74 is only 2.6% above the current price of $328.18. This suggests that much of the good news is already priced in, limiting potential returns unless the company exceeds expectations.
NTRA Technical Analysis
Natera's stock is in a powerful sustained uptrend, with a 1-year price change of +97.03% and a 6-month change of +65.64%. The current price of $328.18 sits near the upper end of its 52-week range, at approximately 95.6% of the range (calculated as (328.18 - 157.425) / (343.18 - 157.425) * 100), indicating strong momentum and bullish sentiment. Trading near the 52-week high of $343.18 suggests the market is rewarding the company's growth trajectory, though it also raises the risk of short-term overextension.
Beta
1.53
1.53x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$157-$343
Price range past year
Annual Return
+89.2%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +4.1% | -1.1% |
| 3m | +55.1% | +3.0% |
| 6m | +75.1% | +15.4% |
| 1y | +89.2% | +16.2% |
| ytd | +43.7% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is accelerating impressively, with Q1 2026 revenue of $696.6 million, up 38.8% year-over-year from $501.8 million in Q1 2025. This growth is driven by the company's oncology segment, particularly Signatera, which is expanding rapidly, while the product revenue of $693.9 million in the latest quarter underscores the broad-based demand for its tests. The multi-quarter trend shows sequential acceleration from $476.1 million in Q4 2024 to $501.8 million in Q1 2025, $546.6 million in Q2 2025, $592.2 million in Q3 2025, $665.5 million in Q4 2025, and $696.6 million in Q1 2026, indicating a robust growth trajectory that is likely to continue as the company penetrates new markets and indications.
Quarterly Revenue
$696644000.0B
2026-03
Revenue YoY Growth
+38.8%
YoY Comparison
Gross Margin
64.8%
Latest Quarter
Free Cash Flow
$92010000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given Natera's negative net income (TTM net margin of -9.03%), the price-to-sales (PS) ratio is the most appropriate valuation metric, as earnings-based multiples are not meaningful. The trailing PS ratio stands at 13.58x, while the forward PS ratio (based on estimated revenue of $5.92 billion for the next fiscal year) is approximately 5.29x, implying that the market expects significant revenue growth to justify the current valuation. The gap between trailing and forward PS suggests that investors are pricing in aggressive expansion, which is consistent with the company's recent growth rates.
PE
-150.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Natera's primary risk is its persistent net losses, with a TTM net margin of -9.0% and a net loss of $85.1M in Q1 2026. The company's operating margin is -13.4%, indicating that it spends heavily on R&D and sales. However, its balance sheet is solid with a current ratio of 3.39 and a low debt-to-equity ratio of 0.125, reducing bankruptcy risk. The company's free cash flow turned positive at $92M TTM, but this is modest relative to its market cap, and continued investment in growth could pressure cash flow.
FAQ
The key risks include: 1) Financial risk: Persistent net losses, with a net margin of -9.0% TTM, could continue if growth slows. 2) Competitive risk: Intense competition in MRD from Guardant Health and Exact Sciences could pressure market share. 3) Macro risk: With a beta of 1.534, the stock is highly sensitive to market downturns. 4) Company-specific risk: Dependence on reimbursement policies and clinical adoption of Signatera. The most severe risk is a combination of growth deceleration and margin compression, which could lead to a 20-30% drop in the stock price.
The 12-month forecast is moderately bullish, with a base case probability of 50% targeting $320-$345, a bull case probability of 30% targeting $350-$375, and a bear case probability of 20% targeting $250-$280. The most likely scenario is the base case, where revenue growth continues at 30-40% but profitability remains elusive. The stock is expected to trade near the average analyst target of $336.74, offering modest upside from the current price of $328.18.
NTRA is overvalued based on trailing metrics, with a P/S ratio of 13.58x, which is high even for a growth company. However, on a forward basis, the P/S ratio of 5.29x (based on estimated revenue of $5.92B) is more reasonable, implying the market expects significant growth. Compared to peers, NTRA trades at a premium, reflecting its leadership and growth prospects. The valuation suggests the market is pricing in continued high growth and eventual profitability, which may or may not materialize.
NTRA is a good buy for growth-oriented investors with a high risk tolerance, given its strong revenue growth and market leadership. However, the stock is trading near its 52-week high with a high P/S ratio, and the average analyst target offers only 2.6% upside, suggesting limited near-term gains. The biggest risk is a growth slowdown or continued losses, which could lead to a sharp correction. For long-term investors who believe in the MRD market's potential, NTRA could be a rewarding addition, but it is not suitable for conservative investors.
NTRA is more suitable for long-term investment, given its high growth potential and the emerging MRD market. The stock's high beta (1.534) and volatility make it risky for short-term trading, as price swings can be significant. For long-term investors, the company's leadership in diagnostics and expanding indications for Signatera provide a multi-year growth runway. A minimum holding period of 3-5 years is recommended to allow the company to achieve profitability and realize its market potential.
